With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.
Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…
Pre-Eclampsia Risk & Rheumatic Disease
Secher et al. evaluated the risk of pre-eclampsia in pregnant patients with RA, axSpA or PsA, assessing the effect of disease activity and disease-modifying anti-rheumatic drugs on this risk.
Improving Bone Mineral Density: Risedronate vs. Denosumab
Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate.
Research Roundup: Abstract Data Presented at ACR Convergence 2021
The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Take our quiz after you read this article. Treat to Target Abstract L06:…
Clinical Insights into Gout Management: Q&A with Dr. Tuhina Neogi
Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often…
Research on Diet & Gout
According to research from Yokose et al. presented at ACR Convergence 2021, regardless of genetic predisposition, diet influences a person’s risk of developing gout.1 Several recent analyses of the Global Burden of Disease (GBD) Study report a disproportionate worsening of gout burden among women, suggesting intensive dietary measures for gout prevention are indicated, especially in…
Highlights from ACR Convergence’s Late-Breaking Abstracts
COVID-19 vaccination, treatments for rheumatic disease and more—the Late-Breaking Abstracts session of ACR Convergence 2021 highlighted six studies with implications for rheumatology.
How to Differentiate Between & Manage Hypereosinophilic Syndromes & EGPA
Hypereosinophilic syndromes and eosinophilic granulomatosis with polyangiitis (EGPA) represent a spectrum of eosinophilic disorders. Amy D. Klion, MD, provided a detailed overview of this spectrum during ACR Convergence 2021.
Multidisciplinary Guidance for Pulmonary Disease in Sjögren’s Syndrome
Lung disease is common, variable and frequently underdiagnosed in patients with Sjögren’s syndrome. An expert pulmonologist and a rheumatologist discussed the diagnosis and management of pulmonary manifestations of Sjögren’s syndrome during ACR Convergence 2021.
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 36
- Next Page »